Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surgery in Metastatic Melanoma Responding to PD-1
NCT04242329Phase 2Withdrawn
- Sponsor
- Region Västra Götaland
- Start
- Mar 2021
- Primary completion
- Sep 2023
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Region Västra Götaland. Primary endpoint: Disease-Free Survival at 12 months. Planned start Mar 2021; status: withdrawn.
Beyond the preview
Go deeper on NCT04242329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04242329.